Tamer Basha Elnaggar

Tamer Basha Elnaggar, MD, BCMAS has over 20 years of experience in the pharmaceutical industry. Tamer Basha currently holds the position of New Products Planning and Pipeline Strategy Lead, Global Oncology Portfolio at Zai Lab, where they provide commercial insights into drug development plans and supports strategic directions and investment decisions. Prior to this, Tamer held various roles at Novartis Oncology, including Global Cell and Gene Pipeline Engagement Lead, Executive Director, Head of Business Excellence and Operations, Region International, and Senior Director, Global Disease Strategy Lead, Solid tumors. Tamer Basha also served as the General Manager for Novartis in Saudi Arabia and the Gulf cluster, where they led launch plans and marketing strategies, achieved significant growth, and restructured teams. Tamer began their career as a Medical Representative at Novartis and completed internships at the Ministry of Health & Population - Egypt and Faculty of Medicine, Ain Shams University. Tamer Basha also co-founded Trimedico, a SME business focused on distribution.

Tamer Basha Elnaggar, MD, BCMAS received their Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from Ain Shams University in 2000. In 2022, they obtained their Board Certified Medical Affairs Specialist (BCMAS) certification from the Accreditation Council for Medical Affairs (ACMA). Tamer Basha has also obtained various additional certifications, including training in Drug Delivery, Drug Discovery and Development, Gene Therapy, Immuno-Oncology and Cell Therapy, Mergers and Acquistions Strategies and Deal execution, Pharma-Biotech Business Development & Licensing, Pharma-Biotech Product and Company Valuation, Clinical Investigator Training Course, Cancer Genomics and Precision Oncology, Essentials of Genetics, and Genetic Testing and Sequencing Technologies. Furthermore, they hold a Corporate Executive and Business Certification from Columbia Business School Executive Education in 2013 and is a member of the Egyptian Syndicate of Medicine through their Doctor of Medicine degree, obtained in 2002 from the Ministry of Health & Population - Egypt. In 2023, they are projected to earn additional certifications in Drug Delivery, Drug Discovery and Development, Gene Therapy, and Immuno-Oncology and Cell Therapy from Harvard Medical School.